Darunavir/ritonavir (DRV/r) is indicated as first-line option in persons with low adherence or before the results of the resistance test, due to the high genetic barrier and potency. § DRV/r 600/100 mg twice daily (BID), is licensed for ART-experienced patients, while for ART-naïve patients the recommended dose is 800/100 mg once daily (QD). § However, in clinical practice, a non negligible proportion of ART-naïve subjects are given DRV /r BID.
Reasons for choosing darunavir/ritonavir 600/100 mg twice daily vs. 800/100 mg once daily in treatment-naive patients: 10 years data from the ICONA cohort.
G. Nunnari;G. F. Pellicanò.
2018-01-01
Abstract
Darunavir/ritonavir (DRV/r) is indicated as first-line option in persons with low adherence or before the results of the resistance test, due to the high genetic barrier and potency. § DRV/r 600/100 mg twice daily (BID), is licensed for ART-experienced patients, while for ART-naïve patients the recommended dose is 800/100 mg once daily (QD). § However, in clinical practice, a non negligible proportion of ART-naïve subjects are given DRV /r BID.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
